After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Zymeworks BC Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Zymeworks BC Inc is $873.33M. A total of 0.52 million shares were traded on the day, compared to an average of 639.43K shares.
In the most recent transaction, EcoR1 Capital, LLC bought 73,953 shares of ZYME for 11.16 per share on Apr 16 ’25. After the transaction, the Director now owns 17,773,727 company shares. In a previous transaction on Apr 17 ’25, EcoR1 Capital, LLC bought 54,760 shares at 11.52 per share. ZYME shares that Director owns now total 17,828,487.
Among the insiders who bought shares, EcoR1 Capital, LLC acquired of 196,438 shares on Apr 04 ’25 at a per-share price of $11.17. This resulted in the Director holding 17,699,774 shares of ZYME after the transaction. In another insider transaction, EcoR1 Capital, LLC bought 120,770 shares at $11.84 per share on Apr 03 ’25. Company shares held by the Director now total 17,503,336.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ZYME has a high of $17.70 and a low of $7.97.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $4.87, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.60.
